COMMUNIQUÉS West-GlobeNewswire

Augustine Therapeutics announces first patient dosed in Phase I clinical trial evaluating lead candidate AGT-100216 for the treatment of Charcot-Marie-Tooth disease
27/05/2025
AGT-100216 is the first HDAC6 inhibitor from Augustine’s pipeline to enter clinical trials LEUVEN, Belgium – 27 May 2025 – Augustine Therapeutics NV (“Augustine” or “the Company”), a biotechnology company focused on [...]
Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S. Composition of Matter Patent Granted for Varoglutamstat
27/05/2025
Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S. Composition of Matter Patent Granted for Varoglutamstat Newly granted U.S. patent expected to provide exclusivity through 2044 with [...]
Press release: Sequana Medical Secures Additional Convertible Financing of EUR 6.3 Million from SFPIM and Other Existing Shareholders
27/05/2025
Sequana Medical Secures Additional Convertible Financing of EUR 6.3 Million from SFPIM and Other Existing Shareholders Continued strong support from major shareholders alfapump® US commercial launch remains on track for [...]
Press Release: Sanofi completes acquisition of DR-0201
27/05/2025
Sanofi completes acquisition of DR-0201 Paris, May 27, 2025. Sanofi announces the completion of its acquisition of DR-0201 , a targeted bispecific myeloid cell engager, from Dren Bio, Inc., a private clinical-stage [...]
Communiqué de presse : Sanofi finalise l’acquisition du DR-0201
27/05/2025
Sanofi finalise l’acquisition du DR-0201 Paris, le 27 mars 2025. Sanofi annonce la finalisation de l’acquisition du DR-0201, un anticorps bispécifique ciblé qui engage les cellules myéloïdes, à Dren Bio, Inc., société [...]
ARCPOINT REPORTS Q1 2025 FINANCIAL RESULTS
27/05/2025
Greenville, South Carolina, May 26, 2025 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the “ Company ” or “ ARCpoint ”) is pleased to report that it has filed its unaudited Q1, 2025 Financial Statements and related [...]
Premier Health Announces CFO Transition
26/05/2025
MONTRÉAL, May 26, 2025 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA ) (the “ Corporation ”), a leading Canadian Healthtech company, announces today that it is proceeding with a transition of the CFO [...]
Liv Hospital and Istinye University Announce Groundbreaking Academic Collaboration with University of Pennsylvania’s Perelman School of Medicine
26/05/2025
ISTANBUL, May 26, 2025 (GLOBE NEWSWIRE) -- Liv Hospital and Istinye University have signed a comprehensive collaboration protocol with the University of Pennsylvania’s Perelman School of Medicine to advance cutting-edge [...]
Alvotech Annual General Meeting to be held June 25, 2025
26/05/2025
The Annual General Meeting of Alvotech will be held on Wednesday June 25, 2025, at 09.00 a.m. CEST at the premises of Arendt & Medernach at 41A, Avenue John F. Kennedy L-1855 Luxembourg, Grand Duchy of Luxembourg. [...]
Iba – Acquisition of Own Shares
26/05/2025
Immediate Release – May 26 th , 2025 Louvain-la-Neuve, Belgium, May 26 th , 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam [...]
IBA – ACQUISITION D’ACTIONS PROPRES
26/05/2025
Publication immédiate – 26 mai 2025 Louvain-la-Neuve, Belgique, 26 mai 2025 - Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam [...]
Valneva to Participate at U.S. and European Investor Conferences in June
26/05/2025
Saint-Herblain (France), May 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and hold investor meetings at several upcoming [...]
Valneva participera à différentes conférences d’investisseurs aux États-Unis et en Europe au cours du mois de juin
26/05/2025
Saint-Herblain (France), le 26 mai 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, annonce aujourd’hui que des membres de son équipe dirigeante effectueront des présentations [...]
Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting
26/05/2025
PRINCETON, N.J., May 26, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of [...]
Brain Cancer Canada Awards $85K to Cutting-Edge Recurrent Glioblastoma Research
26/05/2025
TORONTO, May 26, 2025 (GLOBE NEWSWIRE) -- Brain Cancer Canada is pleased to announce a $85,000 research grant awarded to Dr. Stéphane Angers at the University of Toronto for his project, "Discovery of Druggable [...]
Transactions in Connection with Share Buy-back Program
26/05/2025
Company Announcement COPENHAGEN, Denmark; May 26, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital [...]
Australia Delivers Certainty for US Biotechs in 2025: Avance Clinical Offers Fast Start-Up, Regulatory Predictability, and R&D Rebates
26/05/2025
ADELAIDE, Australia, May 26, 2025 (GLOBE NEWSWIRE) -- As regulatory uncertainty grows in the United States, US biotechs are increasingly looking to Australia as a stable and predictable launchpad for early-phase [...]
MediPharm Labs Begins Production of First Order for International Expansion of Novel Cannabis Metered Dose Portfolio in the EU and United Kingdom Under Blackpoint Sales and Distribution Agreement
26/05/2025
TORONTO, May 26, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids [...]
Transactions under Novonesis’ share buyback program
26/05/2025
Please read the announcement in PDF Attachment 2025_26_Share_buyback_program

Pages